Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease

New England Journal of Medicine

Volumn 343, Issue 26 I, 2000, Pages 1902-1909

  Wise, R ^a   Connett, J ^a   Weinmann, G ^a   Scanlon, P ^a   Skeans, M ^a  

^a Lung Hlth Study Coordinating Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHACHOLINE; PLACEBO; TRIAMCINOLONE ACETATE; TRIAMCINOLONE ACETONIDE;

ADULT; ARTICLE; BONE DENSITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FEMUR; FOLLOW UP; FORCED EXPIRATORY VOLUME; HEALTH SERVICE; HUMAN; LUMBAR SPINE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYMPTOMATOLOGY;

ADMINISTRATION, INHALATION; BONE DENSITY; BRONCHIAL HYPERREACTIVITY; CANDIDIASIS, ORAL; DISEASE PROGRESSION; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HEALTH SERVICES; HOSPITALIZATION; HUMANS; LUNG DISEASES, OBSTRUCTIVE; MALE; MIDDLE AGED; TRIAMCINOLONE;

EID: 0034727828     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200012283432601     Document Type: Article

References (39)

1. Changing smoking patterns and mortality from chronic obstructive pulmonary disease
2. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: The Lung Health Study
3. Alveolar inflammation and its relation to emphysema in smokers
4. 1 in smokers are associated with increased levels of sputum neutrophils
5. Do patients with COPD benefit from treatment with inhaled corticosteroids?
6. Risk factors for accelerated decline among patients with chronic obstructive pulmonary disease
7. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in non-steroid-dependent asthmatics
8. Short-term treatment with budesonide does not improve hyperresponsiveness to adenosine 5′-monophosphate in COPD
9. Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease
10. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD
11. The COPD Guidelines Group of the Standards of Care Committee of the BTS. BTS guidelines for the management of chronic obstructive pulmonary disease
12. Prevalence of inhaled corticosteroid use among patients with chronic obstructive pulmonary disease: A survey
13. Prehospitalization inhaled corticosteroid use in patients with COPD or asthma
14. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomised controlled trial
15. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking
16. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial
17. Chronic Obstructive Pulmonary Disease Early Intervention Trial (Lung Health Study): Baseline characteristics of randomized participants
18. Reference spirometric values using techniques and equipment that meet ATS recommendations
19. Spirometry in the Lung Health Study. I. Methods and quality control
20. The Lung Health Study: Airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation
21. Epidemiology Standardization Project
22. Longitudinal lung function decline in subjects with respiratory symptoms
23. Comparison of outcome measures for patients with chronic obstructive pulmonary disease (COPD) in an outpatient setting
24. Random-effects models for longitudinal data
25. Stochastically curtailed tests in long-term clinical trials
26. Airways hyperresponsiveness, bronchodilator response, allergy and smoking predict improvement in FEV1 during long-term inhaled corticosteroid treatment
27. Measuring compliance with inhaled medication in asthma
28. Adherence with twice-daily dosing of inhaled steroids: Socioeconomic and health-belief differences
29. Glucocorticoid therapy for chronic obstructive pulmonary disease
30. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease
31. Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids: A 4-year prospective study
32. Inhaled beclomethasone improves the course of asthma and COPD
33. Inhaled budesonide therapy for patients with stable COPD
34. Effects of long-term treatment with corticosteroids in COPD
35. Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease
36. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease
37. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: A meta-analysis
38. Effects of high dose inhaled beclomethasone dipropionate, 750 micrograms and 1500 micrograms twice daily, and 40 mg per day oral prednisolone on lung function, symptoms, and bronchial hyperresponsiveness in patients with non-asthmatic chronic airflow obstruction